This journal is recognized as one of the preeminent publications in hypertension. To have achieved this status reflects powerfully on the vision, scholarship, and extraordinary commitment of its first editor, Dr Marvin Moser. The readers, authors, and publishers of The Journal of Clinical Hypertension (JCH) have a great deal to thank him for. Nor should we forget the magnificent contributions and hard work of his team of associate editors, none more prominent than Dr Thomas Pickering.

The journal was initially launched on a compelling premise: that since most hypertension in the community is dealt with by primary care physicians, the articles and features should be directed chiefly at them. Inevitably, over time, the readership broadened to include specialists in the field of hypertension as well as a large following of cardiologists, nephrologists, and endocrinologists, not to mention experts in population health and public policy.

Beyond the self-evident quality of its contents, JCH has been boosted by two major developments. The first was its acceptance for inclusion in Index Medicus, and, more recently, its inclusion in ISI. These important signs of the journal’s prestige and scientific recognition will provide further incentives for authors to submit their highest-quality papers.

A second key step in the journal’s development was the decision by the American Society of Hypertension (ASH) to designate it as an official journal of the Society. The remarkably wide distribution of JCH—almost certainly greater than for any other journal in the field—gives exceptional reach and impact to the Society’s clinical, scientific, and policy missions.

As it has throughout its existence, the journal will continue its growth as an authoritative forum for hypertension in the United States and much of the world. Beyond attracting high level original research, the pages of the journal will convey its expanded participation in the broad fields of cardiovascular, renal, and metabolic medicine. We won’t be timid about publishing provocative editorials, commentaries, and correspondence, not just in the scientific realm but also in matters of public policy. We will always be receptive to differing points of view and debate. One only has to look at journals like The New England Journal of Medicine, Lancet, and JAMA to recognize that readers want to get a good glimpse of relevant developments in the politics, economics, and regulatory issues of their professions.

We are now in the process of assembling our editorial team. Some names will be familiar, others new. Editorial decisions will not be made by just one person; we are sensitive to a world where transparency and conflicts of interest should be acknowledged, so we will do our utmost to ensure that the peer review and editorial processes are as independent and unbiased as possible.

Quite recently, there was a change in the journal’s publisher. The LeJacq company, which started and published JCH for several years, was acquired by Blackwell, which, in turn, was acquired by Wiley. I am delighted to report that our new publishers at Wiley-Blackwell, together with the board of directors of ASH, have strongly encouraged the editors to maintain and expand the innovative features of the journal as well as continue the highest standards of scientific and clinical publishing.